← Leaderboards
Galit Alter
Massachusetts General Hospital
$32,273,423
Attributed
$34,449,470
Total exposure
20
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,449,470 · 20
By mechanism
R01$13,652,948 · 6
U19$8,318,970 · 5
R37$5,834,387 · 1
U01$1,477,970 · 1
R33$1,422,656 · 1
P30$1,311,639 · 1
Top collaborators
- Dan H. Barouch5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Facundo Damian Batista$10,136,331
- Edward T. Ryan$44,052,519
- Athe M. Tsibris$17,945,517
- Simon C Robson$16,000,011
- Daniel Lingwood$10,946,577
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionImmuneAntibodiesMediatingCellsVaccinesVirusImmunityVaccinationViralResponseImmune ResponseAntiviral AgentsLinkNeutralizing AntibodyEpitopesImmune SystemAntigensBaseAntibody ResponseVirus DiseasesLeadT-LymphocyteB-Lymphocytes
Grant awards (67)
Systems Serology Core$297,738
U19 · FY2025 · AI · contact PI
Systems Serology Core$402,350
U19 · FY2024 · AI · contact PI
Antibody Optimization Core$624,302
U19 · FY2023 · AI · contact PI
Systems Serology Core$294,507
U19 · FY2023 · AI · contact PI
Core B$993,882
U19 · FY2022 · AI · contact PI
Antibody Optimization Core$692,869
U19 · FY2022 · AI · contact PI
Demystifying the antiviral activity of the IgG3+ antibody response$604,800
R37 · FY2022 · AI · contact PI
Systems Serology Core$407,400
U19 · FY2022 · AI · contact PI
Defining humoral correlates of immunity against COVID-19$26,206
R37 · FY2022 · AI · contact PI
Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children$960,557
R01 · FY2021 · AI · contact PI
Defining functional humoral correlates of immunity to guide vaccine design$850,980
R01 · FY2021 · AI · contact PI
Core B$758,361
U19 · FY2021 · AI · contact PI
Antibody Optimization Core$689,658
U19 · FY2021 · AI · contact PI
Demystifying the antiviral activity of the IgG3+ antibody response$604,800
R37 · FY2021 · AI · contact PI
Defining the Fc-correlates of protection against influenza$601,251
R01 · FY2021 · AI · contact PI
Systems Serology Core$396,102
U19 · FY2021 · AI · contact PI
Defining humoral correlates of immunity against COVID-19$355,594
R37 · FY2021 · AI · contact PI
SARS-CoV-2 Variant Testing$348,242
R01 · FY2021 · AI · contact PI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease$1,477,970
U01 · FY2020 · CA
Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children$974,009
R01 · FY2020 · AI · contact PI
Mapping and dissecting the role of antibodies in Mtb control$815,165
R56 · FY2020 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$696,167
R01 · FY2020 · AI
Demystifying the antiviral activity of the IgG3+ antibody response$604,800
R37 · FY2020 · AI · contact PI
Defining the Fc-correlates of protection against influenza$544,875
R01 · FY2020 · AI · contact PI
Antibody Optimization Core$532,424
U19 · FY2020 · AI · contact PI
Defining humoral correlates of immunity against COVID-19$391,727
R37 · FY2020 · AI · contact PI
Core B$378,401
U19 · FY2020 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$700,581
R01 · FY2019 · AI
Demystifying the antiviral activity of the IgG3+ antibody response$522,000
R37 · FY2019 · AI · contact PI
Antibody Optimization Core$345,344
U19 · FY2019 · AI · contact PI
Core B$330,343
U19 · FY2019 · AI · contact PI
Demystifying the antiviral activity of the IgG3+ antibody response$810,753
R37 · FY2018 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$729,269
R01 · FY2018 · AI
Killing the Reservoir with Antibodies$468,302
R33 · FY2018 · AI · contact PI
Advanced Technologies Core$356,335
P30 · FY2018 · AI · contact PI
Core B$318,043
U19 · FY2018 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$748,107
R01 · FY2017 · AI
Demystifying the antiviral activity of the IgG3+ antibody response$522,000
R37 · FY2017 · AI · contact PI
Killing the Reservoir with Antibodies$468,302
R33 · FY2017 · AI · contact PI
Advanced Technologies Core$284,838
P30 · FY2017 · AI · contact PI
Demystifying the antiviral activity of the IgG3+ antibody response$956,707
R37 · FY2016 · AI · contact PI
Killing the Reservoir with Antibodies$486,052
R33 · FY2016 · AI · contact PI
Tuning Fc-effector functions of HIV-specific antibodies$876,355
R01 · FY2015 · AI · contact PI
Demystifying the antiviral activity of the IgG3+ antibody response$435,000
R37 · FY2015 · AI · contact PI
Advanced Technologies Core$335,869
P30 · FY2015 · AI · contact PI
Killing the Reservoir with Antibodies$235,561
R21 · FY2015 · AI · contact PI
Tuning Fc-effector functions of HIV-specific antibodies$842,668
R01 · FY2014 · AI · contact PI
Advanced Technologies Core$334,597
P30 · FY2014 · AI · contact PI
Killing the Reservoir with Antibodies$235,561
R21 · FY2014 · AI · contact PI
The role of NK cells during acute HCV infection and antiviral therapy$162,224
U19 · FY2014 · AI · contact PI
Tuning Fc-effector functions of HIV-specific antibodies$672,460
R01 · FY2013 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$407,673
R01 · FY2013 · AI · contact PI
The role of NK cells during acute HCV infection and antiviral therapy$152,490
U19 · FY2013 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$845,738
R01 · FY2012 · AI · contact PI
Tuning Fc-effector functions of HIV-specific antibodies$609,875
R01 · FY2012 · AI · contact PI
The role of NK cells during acute HCV infection and antiviral therapy$205,616
U19 · FY2012 · AI · contact PI
The Innate Immune Signals on B Cells that Induce ADCC Antibodies$437,916
R56 · FY2011 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$433,694
R01 · FY2011 · AI · contact PI
The role of NK cells during acute HCV infection and antiviral therapy$165,696
U19 · FY2011 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$935,323
R01 · FY2010 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$433,874
R01 · FY2010 · AI · contact PI
The role of NK cells during acute HCV infection and antiviral therapy$171,220
U19 · FY2010 · AI · contact PI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp$441,250
R01 · FY2009 · AI · contact PI
Anergizing effect of NK cell receptor expression on HIV-specific CD8+ T cells$249,000
R00 · FY2009 · AI · contact PI
Anergizing effect of NK cell receptor expression on HIV-specific CD8+ T cells$118,697
R00 · FY2009 · AI · contact PI
Anergizing effect of NK cell receptor expression on HIV-specific CD8+ T cells$249,000
R00 · FY2008 · AI · contact PI
Anergizing effect of NK cell receptor expression on HIV-specific CD8+ T cells$90,000
K99 · FY2007 · AI · contact PI